Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

Cancer types with lower mutational load and a non-permissive tumor microenvironment are intrinsically resistant to immune checkpoint blockade. While the combination of cytostatic drugs and immunostimulatory antibodies constitutes an attractive concept for overcoming this refractoriness, suppression...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Baumann, Daniel, Hägele, Tanja, Mochayedi, Julian, Drebant, Jennifer, Vent, Caroline, Blobner, Sven, Noll, Julia Han, Nickel, Irena, Schumacher, Corinna, Boos, Sophie Luise, Daniel, Aline Sophie, Wendler, Susann, Volkmar, Michael, Strobel, Oliver, Offringa, Rienk
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7195409/
https://ncbi.nlm.nih.gov/pubmed/32358491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-15979-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars